Thomas Steyer’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-522,000
| Closed | -$165M | – | 190 |
|
|
2023
Q4 | $165M | Buy |
522,000
+519,800
| +23,627% | +$101M | 0.76% | 37 |
|
|
2023
Q3 | $372K | Hold |
2,200
| – | – | ﹤0.01% | 121 |
|
|
2023
Q2 | $477K | Hold |
2,200
| – | – | ﹤0.01% | 129 |
|
|
2023
Q1 | $400K | Hold |
2,200
| – | – | ﹤0.01% | 152 |
|
|
2022
Q4 | $432K | Sell |
2,200
-77,800
| -97% | -$16.7M | ﹤0.01% | 180 |
|
|
2022
Q3 | $18M | Sell |
80,000
-20,000
| -20% | -$4.05M | 0.1% | 101 |
|
|
2022
Q2 | $12.7M | Sell |
100,000
-250,000
| -71% | -$28.7M | 0.07% | 120 |
|
|
2022
Q1 | $44.4M | Sell |
350,000
-200,000
| -36% | -$22.5M | 0.21% | 74 |
|
|
2021
Q4 | $72M | Sell |
550,000
-150,000
| -21% | -$19.4M | 0.36% | 54 |
|
|
2021
Q3 | $85.6M | Buy |
700,000
+70,000
| +11% | +$8.08M | 0.4% | 58 |
|
|
2021
Q2 | $71.8M | Sell |
630,000
-45,000
| -7% | -$5.26M | 0.29% | 60 |
|
|
2021
Q1 | $81.2M | Sell |
675,000
-25,000
| -4% | -$2.83M | 0.4% | 54 |
|
|
2020
Q4 | $71.1M | Hold |
700,000
| – | – | 0.43% | 56 |
|
|
2020
Q3 | $54.1M | Buy |
700,000
+125,000
| +22% | +$10.7M | 0.37% | 61 |
|
|
2020
Q2 | $64.1M | Buy |
575,000
+7,953
| +1% | +$691K | 0.51% | 51 |
|
|
2020
Q1 | $40.8M | Sell |
567,047
-32,953
| -5% | -$2.82M | 0.35% | 50 |
|
|
2019
Q4 | $45.2M | Buy |
+600,000
| New | +$26.3M | 0.31% | 59 |
|
Other funds holding KRTX
Thomas Steyer's KRTX Position: Q1 2024 in Review
Thomas Steyer sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 522,000 shares — an estimated $165M sold.
Thomas Steyer first reported a position in KRTX in Q4 2019 and held it in 17 quarters. The position peaked at $165M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.
- Thomas Steyer reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Thomas Steyer sold 522,000 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $165M.
- Thomas Steyer first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
- Thomas Steyer's Karuna Therapeutics, Inc. Common Stock position peaked at $165M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Farallon Capital Management's 13F filing for Q1 2024, filed 15 May 2024.